AbbVie Inc.
ABBV · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -6.08 | -0.96 | 9.22 | 0.15 |
| FCF Yield | 5.67% | 8.05% | 8.47% | 9.18% |
| EV / EBITDA | 25.26 | 18.71 | 14.11 | 12.85 |
| Quality | ||||
| ROIC | 10.21% | 9.56% | 14.02% | 12.85% |
| Gross Margin | 69.99% | 62.42% | 70.00% | 68.96% |
| Cash Conversion Ratio | 4.39 | 4.74 | 2.11 | 1.97 |
| Growth | ||||
| Revenue 3-Year CAGR | -1.00% | -1.13% | 8.22% | 19.10% |
| Free Cash Flow Growth | -19.17% | -9.02% | 10.27% | 30.97% |
| Safety | ||||
| Net Debt / EBITDA | 4.18 | 2.75 | 2.27 | 2.83 |
| Interest Coverage | 3.25 | 5.74 | 8.12 | 7.40 |
| Efficiency | ||||
| Inventory Turnover | 4.04 | 4.98 | 4.87 | 5.58 |
| Cash Conversion Cycle | 97.43 | 82.31 | 84.28 | 69.95 |